• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press Releases Translations

马来西亚继续与全球合作伙伴共同对抗C型肝炎

Home > Press Releases Translations

马来西亚继续与全球合作伙伴共同对抗C型肝炎

Man and woman looking at a phone
Kuala Lumpur — 27 Jul 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • 中文
    • English
    • Bahasa Malaysia
    • 中文
    • தமிழ்
    • ไทย
  • 继世界卫生组织(WHO)公布有关C型肝炎自我检测的建议后,马来西亚将成为在有史以来首个C型肝炎自我检测的影响研究中,使用这种创新技术的全球先行者之一。    
  • 这项研究将提供相关影响的关键数据,并有助于切实有效地指导全球C型肝炎自我检测服务的推广和扩展。 

作为全球诊断联盟,促进创新诊断基金会(FIND)正与马来西亚卫生部(MoH)、马来西亚爱滋病理事会(MAC)、世卫组织和被忽视疾病药物研发倡议组织(DNDi)合作,在马来西亚开展C型肝炎病毒自我检测的影响研究。 

继世卫组织在国际爱滋病协会(IAS)会议上分享了对新的C型肝炎病毒自我检测建议后,这项影响研究在2021年世界肝炎日之前,在“C型肝炎防治刻不容缓,马来西亚绝不怠慢”网络研讨会上对外公告。 

今年6月初,马来西亚宣布有条件批准使用ravidasvir治疗C型肝炎。作为这项全球C型肝炎自我检测影响研究的一部分,马来西亚巩固了其2030年消除C型肝炎的承诺。根据估计,马来西亚有超过400,000人患有C型肝炎,但只有1%的患者得到了治疗。自2019年底以来,马来西亚对该疾病采取了分散式护理,使初级医疗机构也能够检测和治疗C型肝炎。 

卫生部肠胃病学和肝病学全国主任拿督莫哈末拉兹阿布哈山分享说:“我们可以从这项影响研究当中了解,对那些不在检测设施覆盖范围的人们来说,自我检测是否可以增进他们的检测率。这也可以提升C型肝炎护理的公平性和可及性。” 

该影响研究将与社区组织马来西亚爱滋病理事会一起合作进行,并建立在通过线上平台JOM TEST所进行的HIV自我检测基础上,旨在检测那些可能被一般检测设施所遗漏掉的人。 

马来西亚爱滋病理事会主席拿督李国忠医生表示:“检测在C型肝炎治疗中继续发挥关键作用,以便接受检测的人能够获得适当的护理。能够为这项影响研究助一臂之力,以了解提供自我检测作为一种附加诊断方法所带来的影响,避免任何人因被忽略而得不到治疗,为此我们深感自豪。” 

马来西亚卫生总监丹斯里诺希山医生表示:“能够走在应对C型肝炎的最前沿,马来西亚深感自豪。有志者事竟成,我们成功实现了这一切。有机会与FIND、DNDi、MAC和WHO等合作伙伴同心协力,一起实现2030年消除C型肝炎的目标,我们感到无比高兴。” 

世卫组织全球爱滋病毒、肝炎、性传播感染项目主任 梅格多赫蒂(Meg Doherty)医生表示:“世卫组织在2021年7月18日举行的国际爱滋病协会会议上,进行了HCV自我检测准则的全球发布。对此我们要赞扬马来西亚的迅速回应,这对扩大重点和弱势人群,以及C型肝炎病毒感染负担较高群体的检测覆盖率具有影响,并有助于国家行动在2030年消除该疾病。 

FIND首席执行长比尔德里格兹(Bill Rodriguez)博士表示,“C型肝炎仍然是世界上大多数国家面对的公共卫生问题。在新准则发布后如此迅速实施这项自我检测研究,马来西亚再次在评估可战胜这种疾病的战略方面处于领先地位,为马来西亚和其他国家提供至关重要的信息。能够成为这个合作伙伴关系的一分子,一起为消除疾病倾注全力,是我们的至高荣幸。” 

DNDi东南亚区总监让米歇尔皮达涅(Jean-Michel Piedagnel)表示:“HCV很独特,因为我们可以通过负担得起的治疗,拟定有效的公共卫生策略以消除疾病。在宣布有条件批准ravidasvir后,这项研究继续使马来西亚成为对抗C型肝炎的战士。能够成为这个团队的一员,引导筛检战略的推陈出新并达致消除疾病的目标,我们深感自豪。” 

世界肝炎日于每年的7月28日举行,旨在提高人们对肝炎的认知。C型肝炎被喻为一种无声的疾病,因为大部分的感染者并不知道自己身体的状况,而且没有表现出任何疾病症状,因此没有寻求治疗。 

关于FIND

作为全球诊断联盟,促进创新诊断基金会(FIND)旨在确保全球各地的人可公平获得可靠的诊断。我们将国家和社群、资助者、决策者、医疗保健提供者和开放商联系起来,促进创新的诊断方法,并使检测成为可持续、具有弹性的卫生系统中不可或缺的一部分。我们致力于通过人人可得的高质量诊断,拯救100万人的性命,并为患者和医疗系统节省高达10亿美元的医疗保健费用。我们是获取COVID-19工具(ACT)加速器诊断支柱,以及世卫组织实验室加强和诊断技术评估合作中心的共同召集人。欲知更多详情,请浏览 www.finddx.org

关于DNDi 

被忽视疾病药物研发倡议组织(Drugs for Neglected Diseases initiative,简称DNDi)是一个非营利性药物研发组织。组织主要为被忽视疾病患者研发新的治疗处方,这其中包括南美锥虫病、昏睡病(非洲人类锥虫病)、利什曼病、丝虫病、足菌肿、霉菌性阴道炎、儿科爱滋病毒/爱滋病、C型肝炎病毒的治疗方法。DNDi也在协调ANTICOV临床试验,为非洲的轻度至中度COVID-19寻找治疗方法。自2003年成立以来,DNDi迄今已交付了9种全新的治疗方案。这其中包括用于治疗利什曼病的新药物组合,两种固定剂量的抗疟药,以及DNDi首次成功研发的新化学实体药物- fexinidazole,此药物也同时于2018年获批准用于治疗两种不同阶段的昏睡病。 dndi.org

关于WHO

世界卫生组织(World Health Organization,简称WHO)是联合国系统内国际卫生问题的指导和协调机构。世卫组织成立于1948年,与6个区域内的194个会员国合作,共同致力于增进世界各地人们的健康,创造一个更安全的未来,以及为弱势群体服务。我们2019至2023年的目标:使受益于全民健康覆盖的人数增加10亿,使受到更充分保护免于突发卫生事件的人数增加10亿,使享有更好的健康和福祉的人数增加10亿。 who.int/

关于MAC

马来西亚爱滋病理事会(Malaysian AIDS Council, 简称MAC)成立于1992年,隶属于卫生部,其使命是代表、动员和加强致力于解决爱滋病毒/爱滋病问题的非政府组织和社群。MAC与其伙伴组织合作开展各种活动,包括倡议和政策改革、培养意识和制定传播材料、开展公众意识运动、举办和组织工作坊和研讨会、推行预防和教育计划,以及提供护理、支援服务和心理辅导。

媒体联系

ROOTS PR Sdn Bhd  

Sara Sabri  
sara.sabri@rootsasia.com 
+60 14 3385945 

Denise Selva  
denise@rootsasia.com 
+60 17 4940557 

Photo credit: Abang Amirrul Hadi – DNDi

Registration & access Hepatitis C Asia Malaysia

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo